The available biomarkers may explain the poor prognosis for just a part of all AML cases; therefore, it was supposed that other new markers might be involved [15], such as minichromosome maintenance complex component 7 (MCM7) gene variants, as they have been reported to be associated with relapse in pediatric and adult AML patients and their overall poor survival rate [9,15,16]. This evidence concerns the gene MCM7 and acute myeloid leukemia.